Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
163 hedge funds and large institutions have $1.41B invested in Clovis Oncology, Inc. in 2016 Q3 according to their latest regulatory filings, with 59 funds opening new positions, 49 increasing their positions, 33 reducing their positions, and 18 closing their positions.
228% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 18
169% more capital invested
Capital invested by funds: $524M → $1.41B (+$887M)
100% more funds holding in top 10
Funds holding in top 10: 5 → 10 (+5)
48% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 33
47% more call options, than puts
Call options by funds: $71M | Put options by funds: $48.3M
34% more funds holding
Funds holding: 122 → 163 (+41)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$28.7M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$13.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$13.4M |
| 4 |
CCM
Consonance Capital Management
New York
|
+$12.8M |
| 5 |
PC
PointState Capital
New York
|
+$12.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$41.8M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$26.1M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$22.5M |
| 4 |
Goldman Sachs
New York
|
-$19.3M |
| 5 |
Morgan Stanley
New York
|
-$14.7M |
CLVS Hedge Fund Activity: Q3 2016 in Review
163 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q3 2016, worth a combined $1.41B — up 169% from $524M a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new CLVS positions and 18 closed out — a net gain of 41 holders — while 49 added to existing stakes and 33 trimmed.
The largest buyer was Balyasny Asset Management, adding an estimated $28.7M. The largest seller was HealthCor Management, cutting an estimated $41.8M.
- 163 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q3 2016, up from 122 in Q2 2016.
- Funds reported $1.41B of Clovis Oncology, Inc. stock for Q3 2016, up 169% quarter-over-quarter.
- 59 funds opened new Clovis Oncology, Inc. positions in Q3 2016 and 18 closed out, a net change of +41 holders.
- The largest Clovis Oncology, Inc. buyer in Q3 2016 was Balyasny Asset Management, an estimated $28.7M added.
- The largest Clovis Oncology, Inc. seller in Q3 2016 was HealthCor Management, an estimated $41.8M sold.
Based on aggregated 13F filings for Q3 2016.